Clarity Pharmaceuticals Ltd
ASX:CU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Saturday Co Ltd
SZSE:002291
|
CN |
|
Nerdy Inc
NYSE:NRDY
|
US |
Clarity Pharmaceuticals Ltd
Interest Income Expense
Clarity Pharmaceuticals Ltd
Interest Income Expense Peer Comparison
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
See Also
What is Clarity Pharmaceuticals Ltd's Interest Income Expense?
Interest Income Expense
5.2m
AUD
Based on the financial report for Jun 30, 2025, Clarity Pharmaceuticals Ltd's Interest Income Expense amounts to 5.2m AUD.
What is Clarity Pharmaceuticals Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
280%
Over the last year, the Interest Income Expense growth was 88%. The average annual Interest Income Expense growth rates for Clarity Pharmaceuticals Ltd have been 280% over the past three years .
